Looking for our Business Solutions? Click here:CloudQuote APIsContact Us

AbbVie (ABBV)

286.20
+2.66 (0.94%)
NYSE · Last Trade: Nov 22nd, 2:13 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
AbbVie (ABBV) Stock Just Got a 5.2% Dividend Increase. Here's How Many Shares You Need to Generate $1,000 a Year.fool.com
This pharmaceutical giant has hiked its payout for 53 years in a row, so it's likely to keep doing so.
Via The Motley Fool · November 21, 2026
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?fool.com
Eli Lilly's revenue is climbing at a pace AbbVie can't match, yet AbbVie trades at a noticeably lower earnings multiple.
Via The Motley Fool · November 20, 2026
Cannabis Stocks’ Headline Gains Mask a Narrow, Quality-Led Rallychartmill.com
Via Chartmill · November 20, 2026
These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buysfool.com
They have excellent long-term prospects.
Via The Motley Fool · November 16, 2026
AbbVie (NYSE:ABBV): A Quality Investing Candidate With Caveatschartmill.com
Via Chartmill · November 3, 2026
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?fool.com
These healthcare dividend stocks appeal to investors in different ways.
Via The Motley Fool · November 14, 2026
3 Dividend Stocks Built for a Market Priced Like It's 1999fool.com
With stocks arguably priced like it's 1999, these three dividend payers could help you weather what comes next.
Via The Motley Fool · November 13, 2026
Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on Itfool.com
The world's largest healthcare company is making shrewd investments in its future.
Via The Motley Fool · November 12, 2026
3 Pharmaceutical Stocks That Offer Safety and Growthmarketbeat.com
AbbVie, Merck and Gilead Sciences offer growing dividends alongside pipeline-driven growth, making pharmaceutical stocks a defensive option as investors seek shelter from market volatility.
Via MarketBeat · November 12, 2026
Stock Market Sell-Off: Meet the Unstoppable Vanguard ETF Obliterating the S&P 500 in 2026fool.com
Value stocks are crushing growth stocks as investors sour on the artificial intelligence trade.
Via The Motley Fool · November 10, 2026
MarketBeat Week in Review – 11/2 - 11/6marketbeat.com
Via MarketBeat · November 7, 2026
2 unpopular stocks that deserve some love and 1 facing challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via StockStory · November 5, 2026
3 Dividend Kings to Buy in November and Never Sellfool.com
These are arguably among the most reliable dividend payers.
Via The Motley Fool · November 5, 2026
2 Growth Stocks to Buy in November Without Any Hesitationfool.com
They have both outperformed the broader equity market over the long run.
Via The Motley Fool · November 5, 2026
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Testmarketbeat.com
AbbVie posted Q3 revenue of $17.4 billion and raised EPS guidance as Skyrizi and Rinvoq offset Humira's decline, prompting analyst price target hikes and a stock move to fresh highs.
Via MarketBeat · November 2, 2026
The Best Dividend Stocks to Buy With $5,000 in Novemberfool.com
AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market.
Via The Motley Fool · November 2, 2026
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?fool.com
AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.
Via The Motley Fool · November 2, 2026
Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combofool.com
AbbVie replaced one megablockbuster already. It may have found its next one.
Via The Motley Fool · November 2, 2026
The top 5 analyst questions from AbbVie’s Q3 earnings call
AbbVie’s third quarter was marked by a positive market reaction, attributed to robust sales growth across its immunology and neuroscience portfolios. Managem...
Via StockStory · November 1, 2026
AbbVie: 3 Key Takeaways for Long-Term Investorsfool.com
Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety.
Via The Motley Fool · October 31, 2026
Is AbbVie a Buy After Its Latest Earnings Report?fool.com
Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.
Via The Motley Fool · October 31, 2026
ABBV Q3 deep dive: Immunology and neuroscience drive growth, pipeline progress continues
Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with sales up 10.3% year on year to $17.4 billion. Its non-GAAP ...
Via StockStory · October 31, 2026
AbbVie (ABBV) Q3 2026 Earnings Call Transcriptfool.com
Skyrizi and Rinvoq drive double-digit growth as management raises full-year guidance.
Via The Motley Fool · October 30, 2026
What AbbVie (ABBV) Said on Its Q3 Earnings Callmarketbeat.com
AbbVie (NYSE:ABBV) reported third-quarter 2026 results above its guidance midpoint and raised its full-year revenue and adjusted earnings outlook, citing continued growth from its immunology and neuroscience portfolios. The company posted adjusted earnings per share of $3.82, $0.07 above the midpoi
Via MarketBeat · October 30, 2026
AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates
Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non...
Via StockStory · October 30, 2026